Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review
Pharmaceutics · 25.02.2023 · 15 (3) · 766
DOI: 10.3390/pharmaceutics15030766 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 25.02.2023. Verfasst von Manuel Busto-Iglesias und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ISCIII, Xunta de Galicia, European Union (EU).
Abstract (Originalsprache)
Biological drugs, especially those targeting anti-tumour necrosis factor α (TNFα) molecule, have revolutionized the treatment of patients with non-infectious uveitis (NIU), a sight-threatening condition characterized by ocular inflammation that can lead to severe vision threatening and blindness. Adalimumab (ADA) and infliximab (IFX), the most widely used anti-TNFα drugs, have led to greater clinical benefits, but a significant fraction of patients with NIU do not respond to these drugs. The therapeutic outcome is closely related to systemic drug levels, which are influenced by several factors such as immunogenicity, concomitant treatment with immunomodulators, and genetic factors. Therapeutic drug monitoring (TDM) of drug and anti-drug antibody (ADAbs) levels is emerging as a resource to optimise biologic therapy by personalising treatment to bring and maintain drug concentration within the therapeutic range, especially in those patients where a clinical response is less than expected. Furthermore, some studies have described different genetic polymorphisms that may act as predictors of response to treatment with anti-TNFα agents in immune-mediated diseases and could be useful in personalising biologic treatment selection. This review is a compilation of the published evidence in NIU and in other immune-mediated diseases that support the usefulness of TDM and pharmacogenetics as a tool to guide clinicians’ treatment decisions leading to better clinical outcomes. In addition, findings from preclinical and clinical studies, assessing the safety and efficacy of intravitreal administration of anti-TNFα agents in NIU are discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain.
- Pharmacology Group, Health Research Institute of Santiago de Compostela (FIDIS), 15706 Santiago de Compostela, Spain.
- Ophthalmology Department, Bellvitge University Hospital, 08907 Barcelona, Spain.
- Ophthalmology Department, University Clinical Hospital of Santiago Compostela (SERGAS), 15706 Santiago de Compostela, Spain.
- Musculoskeletal Pathology Group, Hospital Clínico San Carlos, Instituto Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.
ORCID-Profile: Manuel Busto-Iglesias, Lorena Rodríguez-Martínez, Carmen Antía Rodríguez-Fernández, Luis Rodríguez-Rodríguez, Anxo Fernández-Ferreiro, Cristina Mondelo-García
Förderung
- ISCIII
- Xunta de Galicia
- European Union (EU)
Zitieren
APA
Busto-Iglesias, M., Rodríguez-Martínez, L., Rodríguez-Fernández, C. A., González-López, J., González-Barcia, M., de Domingo, B., Rodríguez-Rodríguez, L., Fernández-Ferreiro, A., & Mondelo-García, C. (2023). Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review. Pharmaceutics, 15(3), 766. https://doi.org/10.3390/pharmaceutics15030766
Vancouver
Busto-Iglesias M, Rodríguez-Martínez L, Rodríguez-Fernández CA, González-López J, González-Barcia M, de Domingo B, et al. Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review. Pharmaceutics. 2023;15(3):766. doi:10.3390/pharmaceutics15030766
BibTeX
@article{BustoIglesias2023,
author = {Busto-Iglesias, Manuel and Rodríguez-Martínez, Lorena and Rodríguez-Fernández, Carmen Antía and González-López, Jaime and González-Barcia, Miguel and de Domingo, Begoña and Rodríguez-Rodríguez, Luis and Fernández-Ferreiro, Anxo and Mondelo-García, Cristina},
title = {Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {3},
pages = {766},
doi = {10.3390/pharmaceutics15030766}
}
EUVIMED